Innate Pharma Capital Reinvestment Ratio
Innate Pharma capital reinvestment ratio. Innate Pharma (IPHA) has a Capital Reinvestment Ratio of 0.09x as of June 2024, meaning it reinvests 0% of its operating cash flow ($3.04 Million) in capital expenditures ($283.00K). Check Innate Pharma cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Capital Reinvestment Ratio of Innate Pharma (2006–2019)
Capital reinvestment ratio of Innate Pharma from 2006 to 2019. This chart tracks Innate Pharma's Capital Reinvestment Ratio across 4 annual periods. Also explore IPHA net asset momentum to track the company's year-over-year net asset growth rate.
Innate Pharma Capital Reinvestment Ratio by Year (2006–2019)
Innate Pharma capital reinvestment ratio by year from 2006 to 2019. For the full cash flow conversion analysis, see IPHA operating cash flow.
| Year | Reinvestment Ratio | Operating CF (USD) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2019 | 1.87x | $34.92 Million | $65.40 Million | ▲ +5163.6% |
| 2015 | 0.04x | $207.91 Million | $7.40 Million | ▲ +43.5% |
| 2011 | 0.02x | $12.99 Million | $322.00K | ▼ -98.8% |
| 2006 | 2.09x | $360.00K | $752.00K | — |